(P1) Shares of cannabis producer Tilray Brands (TLRY) surged 10% Thursday as investors reacted to the U.S. government’s historic decision to reclassify medical marijuana as a Schedule III drug, a move that could significantly alter the financial landscape for the industry.
(P2) "Federal rescheduling would mark an important advancement for medical cannabis in the United States, paving the way for more research, wider physician involvement, and better patient access," Tilray CEO Irwin D. Simon said in a statement, highlighting the transformative potential of the policy shift.
(P3) The stock, which had already climbed 14% in the previous session on speculation, traded near $8.68 on Thursday. The rally cooled later in the day as traders digested the nuances of the ruling, which applies only to FDA-approved and state-licensed medical products, not the broader adult-use market. The initial excitement saw the stock experience one of its sharpest two-day moves in months.
(P4) While the rescheduling does not legalize marijuana at the federal level, it is a critical de-risking event. The change to Schedule III, a category for drugs with a moderate-to-low risk of addiction like ketamine and testosterone, is expected to eliminate the punitive 280E tax burden, which has historically crippled profitability for cannabis companies. The full impact, however, remains tied to a rulemaking process that is still unfolding.
The U.S. Department of Justice confirmed the policy shift on April 23, following a directive from the Trump administration. This move allows state-licensed medical marijuana producers to claim tax benefits previously unavailable under the substance's former Schedule I classification, which grouped it with heroin and LSD. Experts suggest the reclassification will also lower barriers for scientific research into cannabis-derived substances.
For Tilray, the change provides an opening to activate its U.S. strategy. The company plans to use its existing infrastructure, including a $150 million global medical cannabis business and a $300 million pharmaceutical distribution platform, to penetrate the U.S. medical market. Despite the bullish sentiment, Tilray's fundamentals present a mixed picture. The company reported third-quarter revenue of $206.73 million, beating consensus, but its adjusted EPS of $0.02 missed estimates.
The rally's initial momentum faded as investors recognized the limited scope of the immediate changes. The federal process is ongoing, and a postponed DEA hearing on the matter introduces uncertainty about the timeline. This leaves the market in a "process story," where the full benefits of rescheduling depend on further regulatory actions and clarifications. The distinction between medical and recreational cannabis remains a critical factor, with the latter still federally illegal, creating a complex operating environment for companies like Tilray, Canopy Growth, and other sector players.
This article is for informational purposes only and does not constitute investment advice.
